A shingles vaccine might be one of our most powerful new tools for fighting dementia.
April 15, 2026
Original Paper
Recombinant zoster vaccination in patients with dementia is associated with improved survival and better cognitive preservation
medRxiv · 10.64898/2026.04.09.26350509
The Takeaway
Researchers found that people who received the Shingrix vaccine (for shingles) had much better survival rates and significantly slower brain decline after a dementia diagnosis. This is an incredible 'off-label' benefit that nobody saw coming. It suggests that preventing common viral flares might be a secret key to protecting the aging brain. While it’s not a 'cure' for dementia, it offers a safe, existing way to potentially give patients years of better cognitive health. It’s a massive win found in an unexpected place, proving that our immune health is deeply tied to our brain’s longevity. A simple shot might be doing way more for our brains than we thought.
From the abstract
Dementia affects tens of millions of people worldwide, yet disease-modifying treatments remain strikingly limited. Although the recombinant zoster vaccine Shingrix has been associated with reduced dementia incidence, its potential influence on individuals already living with dementia is unknown. Here, we followed a propensity-score matched cohort of 68,960 US dementia patients using a nationwide electronic health record network, comparing Shingrix recipients within two years of diagnosis to reci